Joanne Wuensch

Medtech name IRhythm Technologies Inc (NASDAQ: IRTC) is redefining how cardiac arrhythmias are monitored, which makes the stock an attractive buy, according to BMO Capital Markets.  The Analyst BMO analyst Joanne Wuensch initiated coverage of iRhythm Technologies' stock with an...

Insulet Corporation (NASDAQ: PODD) is up 80.5 percent year-over-year, and even last quarter’s bottom-line miss can’t deter the biotech’s bulls. The Rating BMO Capital Markets analyst Joanne Wuensch initiated coverage of Insulet Corp. with an Outperform rating and $90 price...

With a presence across 10 markets, leadership in some segments and a "robust" product pipeline, Becton Dickinson and Co (NYSE: BDX) is "more than just needles and syringes," according to BMO Capital Markets.  The Analyst BMO analyst Joanne Wuensch initiated coverage...

The medical device company Penumbra Inc (NYSE: PEN) issued a consensus-beating earnings report Nov. 7.  The Analyst BMO Capital Markets' Joanne Wuensch downgraded Penumbra from Outperform to Market Perform and reduced the price target from $117 to $110. The Thesis The analyst said...

Abbott Laboratories (NYSE: ABT) had a busy 2017 after acquiring Alere and St. Jude Medical, earning the stock a nod of approval from a Wall Street analyst. The Analyst BMO Capital Markets' Joanne Wuensch upgraded Abbott's stock rating from Market Perform to Outperform with a price target...

BMO Capital Markets has downgraded Endologix, Inc. (NASDAQ: ELGX) to Market Perform from Outperform after FDA’s request of two-year follow-up data from Nellix clinical study, instead of a one-year follow-up. The news sent the company's shares in to a tailspin. The Nellix Issue The Nellix...

Cooper Companies Inc (NYSE: COO) reported its third-quarter results after Thursday's market close. The company said it earned $2.30 per share in the quarter on revenue of $514.7 million, exceeding the $2.29 per share and $511.8 million Wall Street analysts were expecting. According to Joanne...